Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Butropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.60 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.60 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.60 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 4/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butropium SCHEMBL1650524 | 1.00 | BLM (0.64) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL30185784 | 1.00 | BLM (0.64) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL11561521 | 1.00 | BLM (0.64) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Butropium SCHEMBL29388793 | 0.99 | CHRM2 (0.63) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Bromide SCHEMBL29840597 | 0.88 | BLM (0.77) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL29371652 | 0.87 | BLM (0.71) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL24707 | 0.87 | BLM (0.71) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL29361010 | 0.86 | CHRM2 (0.71) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| Xenytropium SCHEMBL30428452 | 0.86 | CHRM2 (0.71) | BLMCHRM2PABPC1CYP2C19CHRM1 | |
| SCHEMBL14652328 | 0.81 | CHRM2 (0.77) | BLMCHRM2PABPC1CYP2C19CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-0580860-B2 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| JP-61233683-A | — | — | None | — | — | JP | disclosed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-0580860-A1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-02-02 | — | — | EP | disclosed |
| EP-0002051-B1 | USE OF BUTOXYBENZYLHYOSCYAMINE BROMIDE IN PHARMACEUTICAL COMPOSITIONS AGAINST DEAFNESS AND TINNITUS | Eisai Co., Ltd. (JP) | 1988-02-03 | — | — | EP | disclosed |
| JP-S61233683-A | HYOSCYAMINE DERIVATIVE | ROLLER JAPAN KK | 1986-10-17 | — | — | JP | disclosed |
| EP-0002051-A1 | Use of butoxybenzylhyoscyamine bromide in pharmaceutical compositions against deafness and tinnitus | Eisai Co., Ltd. (JP) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM2 4475/4885CHRM1 4534/4885CHRM5 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.